Alexion Pharmaceuticals, Inc. (ALXN) Insider Trading: HANTSON LUDWIG sold 2553 Shares

Saturday, 13 Jan, 2018

During the same quarter in the prior year, the company posted $1.23 earnings per share. (ALXN) traded up $0.68 during midday trading on Friday, reaching $123.16. At a certain point in the past four quarters, the shares traded as low as $96.18 but made a 26.28% recovery since then.

Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by equities research analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating in a research report issued to clients and investors on Monday, December 18th, Marketbeat reports. It has underperformed by 34.82% the S&P500.

Orbimed Advisors Llc, which manages about $6.70B and $10.46B US Long portfolio, upped its stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 649,200 shares to 749,200 shares, valued at $109.57 million in 2017Q3, according to the filing. If Amgen Inc. (NASDAQ:AMGN) shares can stay above the price resistance around $184.25 a share, that could help propel Amgen Inc. They expect $1.08 earnings per share, down 1.82% or $0.02 from last year's $1.1 per share. Visa Inc now has $272.24 billion valuation. The stock decreased 0.28% or $0.34 during the last trading session, reaching $121.46. About 69,726 shares traded. Pluristem Therapeutics Inc. (PSTI) has declined 7.80% since January 12, 2017 and is downtrending. It has outperformed by 18.44% the S&P500.

Since July 31, 2017, it had 0 insider purchases, and 6 selling transactions for $2.74 million activity. HPM Partners LLC increased its holdings in shares of Alexion Pharmaceuticals by 267.2% in the 2nd quarter. NEXT Financial Group Inc raised its position in shares of Alexion Pharmaceuticals by 37.7% in the third quarter. O'Neill Julie had sold 4,375 shares worth $636,285 on Thursday, August 31. Wagner Heidi L had sold 120 shares worth $16,800.

In the past 52-week period, shares of Alexion Pharmaceuticals, Inc. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have given a buy rating to the company. Therefore 82% are positive. Clearbridge Lc reported 0.44% in Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The company was initiated on Friday, September 23 by Wedbush. (NASDAQ:ALXN) earned "Buy" rating by Nomura on Monday, July 17. (NASDAQ:ALXN) earned "Buy" rating by UBS on Thursday, February 4. SunTrust Banks reissued a buy rating and issued a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. The company presently has a consensus rating of "Buy" and a consensus target price of $153.61. Morgan Stanley maintained Alexion Pharmaceuticals, Inc. As per Friday, July 28, the company rating was maintained by Morgan Stanley. As per Thursday, September 14, the company rating was maintained by Piper Jaffray.

Menora Mivtachim Holdings Ltd. holds 0.06% of its portfolio in Pluristem Therapeutics Inc. for 1.00 million shares. Congress Asset Ma stated it has 39,028 shares. (NASDAQ:UNFI). Wellington Shields Cap Ltd holds 0.49% or 89,020 shares in its portfolio. Lagoda Invest Mgmt Ltd Partnership owns 8,905 shares or 0.45% of their United States portfolio. (NASDAQ:ALXN). Greenleaf Trust invested in 169 shares or 0% of the stock.

Ownership at Alexion Pharmaceuticals, Inc. Teacher Retirement System Of Texas has invested 0.09% in Alexion Pharmaceuticals, Inc. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Fukoku Mutual Life Insur has 0.02% invested in Alexion Pharmaceuticals, Inc. Balyasny Asset Management Ltd Liability Company invested 0.1% of its portfolio in Alexion Pharmaceuticals, Inc. The total amount of shares outstanding is 223.21 million, giving the company a market capitalization of about 27.34 billion. Cadence Cap Ltd Limited Liability Company accumulated 6,001 shares.

Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company's stock valued at $124,037,000 after acquiring an additional 864,967 shares during the last quarter. CRANSTON MARY B also sold $1.07M worth of Visa Inc. The rating was initiated by Deutsche Bank with "Buy" on Thursday, November 3. $707,561 worth of Visa Inc. 2,970 shares were sold by HEFFERNAN JAMES P, worth $126,077.

Investors sentiment increased to 1.25 in Q3 2017. Its down 0.59, from 2.47 in 2017Q2. 5 funds opened positions while 27 raised stakes. (NYSE:V) for 113,632 shares. 2,280 are owned by Chicago Equity Prtn Ltd Liability Com. Elk Creek Prtn Limited invested 0.03% of its portfolio in Alexion Pharmaceuticals, Inc. Strs Ohio invested 0.34% in Alexion Pharmaceuticals, Inc. The shares of the corporation went up by 1.55% during the previous month. Carroll Fin Associate holds 0% or 168 shares. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported. Brown Advisory holds 6,840 shares. (NYSE:V) for 523,234 shares. Elizabeth Park Cap Ltd invested 0.44% in Southern First Bancshares, Inc. Sumitomo Mitsui Holding holds 626,693 shares. The Pennsylvania-based Nationwide Fund Advsr has invested 0% in Halozyme Therapeutics, Inc. Barclays Public Limited holds 108,196 shares. (NASDAQ:AMGN) higher to the next line of resistance at $185.64 a share. It also reduced its holding in Verisign Inc (NASDAQ:VRSN) by 80,039 shares in the quarter, leaving it with 316,997 shares, and cut its stake in Facebook Inc (NASDAQ:FB). Aes Corp (NYSE:AES) was reduced too. (NYSE:V), 33 have Buy rating, 0 Sell and 7 Hold. Therefore 67% are positive.

Additionally, according to the most recent 13F filing from Alexion Pharmaceuticals, Inc. The firm earned "Overweight" rating on Monday, May 16 by Barclays Capital. (NASDAQ:ALXN) on Monday, December 18 to "Outperform" rating. The rating was maintained by Citigroup with "Buy" on Tuesday, September 20. The stock of Visa Inc. On Tuesday, November 24 the stock rating was maintained by RBC Capital Markets with "Sector Perform". The stock has "Neutral" rating by BTIG Research on Thursday, January 7. The company was upgraded on Friday, October 28 by FBR Capital. (NASDAQ:ALXN) was sold by HANTSON LUDWIG on Tuesday, January 2. Cowen & Co maintained the stock with "Buy" rating in Friday, July 14 report.